Subscribe to our newsletter

Investor Resources

Who We Are

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences has its registered office in Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

Our common shares are listed for trading on the Nasdaq Market (LMNL).

Stock Quote
NASDAQLMNL
OUR DEVELOPMENT PROGRAMS

GPR84 Antagonist

The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the linkage and regulation of the inflammatory and metabolic response, and promotes fibrosis. Learn more.


OXER1 Antagonist 

OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1 is highly selective for 5 oxo ETE, one of the most powerful chemo attractants and activators of eosinophils. Learn more.

Recent News
Nov 25, 2022

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting of shareholders on January 20th, 2023, to seek...

Nov 9, 2022

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of $33.1 million Net loss from continuing...

Nov 8, 2022

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9,...

More News

Latest Events
Thursday, November 10, 2022
8:30am - 9:30am EST

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and...

Wednesday, August 10, 2022
8:30am - 9:30am EDT
Investor Resources